Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Cell surface-targeted immunocytokines program systemic anti-tumor immunity

ABSTRACT: Systemically-administered cytokines are potent immunotherapy agents but exhibit severe dose-limiting toxicities. To overcome this challenge, cytokines have been engineered for intratumoral retention following local delivery. However, despite inducing regression of treated lesions, tumor-localized cytokines often elicit only modest abscopal effects at distal untreated tumors. Here we report a localized cytokine therapy that safely elicits potent systemic anti-tumor immunity by engineered targeting of the ubiquitous leukocyte receptor CD45. CD45-targeted immunocytokines (αCD45-Cyt) exhibit significantly diminished internalization rates relative to their wild-type counterparts; this prolonged surface retention sustains downstream pSTAT induction and enables both cis and trans signaling between lymphocytes. Intratumoral αCD45-Cyt administration led to decoration of leukocytes in the tumor and tumor-draining lymph node (TDLN) without systemic exposure. Therapeutically, a single dose of αCD45-IL12 followed by a single dose of αCD45-IL15 eradicated both treated tumors and untreated distal lesions in multiple syngeneic mouse tumor models. Mechanistically, prolonged exposure to αCD45-Cyt in the tumor and TDLN reprogrammed CD8+ T cells in the TDLN to exhibit an anti-viral transcriptional signature and expanded tumor-specific effector T cells in both the tumor and TDLN. CD45 anchoring represents a broad platform for protein retention by host immune cells for use in immunotherapy.

ORGANISM(S): Mus musculus

PROVIDER: GSE252949 | GEO | 2024/07/07

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNAseq profiling of tumor, tumor-draining-lymph nodes, blood and tumor-associated macrophages of MC38 mice treated with the PI3Kg inhibitor AZD3458 and a combination of AZD3458 and anti-PD-1

Project description:RNAseq profiling of AZD3458 monotherapy and combination treatment with anti-PD-1 of whole tumors, isolated tumor macrophages (Mac) (CD45+CD11b+F4/80+), whole blood (PB) and tumor draining lymph nodes (TDLN) were assessed to elucidate further mechanisms leading to enhanced combination activity.

2021-02-28 | E-MTAB-10057 | biostudies-arrayexpress

Gene array data of tumour draining lymph node fibroblastic reticular cells (FRCs)

Project description:Lymph node (LN) stromal cells, particularly fibroblastic reticular cells (FRCs), provide critical structural support and regulate immunity, tolerance and transport properties of LNs. In many tumors, LN metastasis is predictive of poor prognosis, however, stromal contribution to the evolving microenvironment of tumor draining LNs (TDLN) remains poorly understood. Here we present comparative transcriptional data of resting and TDLN FRCs after different time points of tumor drainage. FRCs were isolated from lymph nodes and FACS sorted based on the expression of CD45-, CD31- and PDPN+

2016-07-11 | GSE73728 | GEO

Tumor invasion in draining lymph nodes is associated with Treg accumulation in breast cancer patients

Project description:Tumor-draining lymph node (TDLN) invasion by metastatic cells in breast cancer correlates with poor prognosis and is associated with local immunosuppression, which can be partly mediated by regulatory T cells (Tregs). Here, we study Tregs from matched tumor-invaded and non-invaded TDLNs, and breast tumors. We observe that Treg frequencies increase with nodal invasion, that Tregs express higher levels of co-inhibitory/stimulatory receptors than effector cells. Also, while Tregs show conserved suppressive function in TDLN and tumor, conventional T cells (Tconvs) in TDLNs proliferate and produce Th1-inflammatory cytokines, but are dysfunctional in the tumor. We describe a common transcriptomic signature shared by Tregs from tumors and nodes, including CD80, which is significantly associated with poor patient survival. TCR RNA-sequencing analysis indicates trafficking between TDLNs and tumors and ongoing Tconv/Treg conversion. Overall, TDLN Tregs are functional and express a distinct pattern of druggable co-receptors, highlighting their potential as targets for cancer immunotherapy.

2020-05-26 | E-MTAB-9112 | biostudies-arrayexpress

Tumor invasion in draining lymph nodes is associated with Treg accumulation in breast cancer patients.

Project description:Tumor-draining lymph node (TDLN) invasion by metastatic cells in breast cancer correlates with poor prognosis and is associated with local immunosuppression, which can be partly mediated by regulatory T cells (Tregs). Here, we study Tregs from matched tumor-invaded and non-invaded TDLNs, and breast tumors. We observe that Treg frequencies increase with nodal invasion, and express higher levels of co-inhibitory/stimulatory receptors than effector cells. Also, while Tregs show conserved suppressive function in TDLN and tumor, conventional T cells (Tconvs) in TDLNs proliferate and produce Th1-inflammatory cytokines, but are dysfunctional in the tumor. We describe a common transcriptomic signature shared by Tregs from tumors and nodes, including CD80, which is significantly associated with poor patient survival. TCR RNA-sequencing analysis indicates trafficking between TDLNs and tumors and ongoing Tconv/Treg conversion. Overall, TDLN Tregs are functional and express a distinct pattern of druggable co-receptors, highlighting their potential as targets for cancer immunotherapy.

2020-05-22 | GSE115545 | GEO

Radiation and anti-PD-L1 synergize by stimulating a stem-like T cell population in the tumor-draining lymph node

Project description:Radiotherapy (RT) and anti-PD-L1 synergize to enhance local and distant (abscopal) tumor control. However, clinical results in humans have been variable. With the goal of improving clinical outcomes, we investigated the underlying synergistic mechanism focusing on a TCF-1+ PD-1+ CD8+ stem-like T cell subset in the tumor-draining lymph node (TdLN). We found that RT + anti-PD-L1 induces a novel differentiation program in the TdLN stem-like population which leads to their expansion and differentiation into effector cells within the tumor. We also found that optimal synergy between RT + anti-PD-L1 is dependent on the TdLN stem-like T cell population as either blockade of TdLN egress or specific stem-like T cell depletion reduced tumor control. Together, these data demonstrate a multistep stimulation of stem-like T cells following combination therapy which is initiated in the TdLN and completed in the tumor.

2024-02-22 | GSE256178 | GEO

scRNA-seq of B16F10 infiltrating CD45+ immune cells from Kcnj2f/f and Kcnj2CKO mice

Project description:The tumor microenvironment (TME) is a unique niche governed by constant crosstalk within and across all intratumoral cellular compartments.We sorted CD45+ immune cells from Kcnj2f/f and Kcnj2CKO mice and performed 10X single cell sequencing to illustrate the impact of Kcnj2 on TME.

2024-09-09 | GSE183783 | GEO

Non-homogenous intratumor ionizing radiation doses synergize with PD1 and CXCR2 blockade

Project description:Partial tumor irradiation combining low dose radiation with high dose radiation within the same tumor mass would prompt an antitumor effect when combined with immunomodulators. Partial irradiations (50%/50%) of subcutaneous MC38 tumors with millimetric precision to deliver low dose radiation (2Gy) and high dose radiation (16Gy) within the same tumor was performed and single-cell RNA sequencing of CD45+ cells analysis was done in both the two part of the tumor to identify tumor-infiltrating immune cells.

2024-09-06 | GSE262699 | GEO

Clonal and functional patterns of emigrating Treg cells according to locations

Project description:Single-cell TCR and RNA sequencing of recovered T cells in mLN, cLN, tdLN and tumor bed 24 hours post inoculation of CFSE in mLN.

2023-07-01 | E-MTAB-12846 | biostudies-arrayexpress

NanoString Analysis of Gene Expression in B16.F10 Tumors Treated with the cGAS Activator, NanoISD

Project description:Characterization of the immune profile (i.e. tumor RNA) of a murine B16.F10 tumor 6 hours post a single 100 µL intratumoral injection of 2 µg NanoISD, Free D-PDB at an equivalent dose, or PBS.

2021-09-01 | GSE183144 | GEO

Transcriptional differences between intratumoral CD8+ T cells in young and aged tumors at single cell resolution

Project description:Single-cell RNA sequencing of intratumoral CD8+ T cells (and CD45+ cells) from young and aged mice

2024-03-14 | GSE255373 | GEO